GSK Secures High Blood Pressure Drug in $950 Million Deal

GSK Secures High Blood Pressure Drug in $950 Million Deal

GSK Plc agreed to buy 35Pharma Inc., a biotech with an early-stage high blood pressure drug, as the UK pharmaceutical company expands into cardiovascular medicine.

📰 Original Source

Read full article at Bloomberg →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.